Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAESTRA 2
2025-522748-42-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of INCB123667 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Incyte. Primary endpoints: Progression-free survival by blinded independent central review and Overall survival. Planned start Jul 2026; status: authorised.
02
Drugs
INCB123667
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2025-522748-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522748-42-00.